Catalase/Superoxide Dismutase (SOD) and Catalase/Paraoxonase (PON) Ratios May Implicate Poor Glycemic Control

Sundaram, 1996, Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications, Clin Sci, 90, 255, 10.1042/cs0900255 Baynes, 1991, Role of oxidative stress in development of complications in diabetes, Diabetes, 40, 405, 10.2337/diabetes.40.4.405 Maxwell, 1997, Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in non-insulin-dependent diabetes mellitus, Ann Clin Biochem, 34, 638, 10.1177/000456329703400607 Hayakawa, 1990, Free radicals and diabetes mellitus, Nippon Ronen Igakkai Zasshi/Jpn J Geriatr, 27, 149 Sözmen, 1999, Catalase and paraoxonase activities in hypertensive type 2 DM; correlation with glycemic control, Clin Biochem, 32, 423, 10.1016/S0009-9120(99)00034-X Mackness, 1996, Paraoxonase; biochemistry, genetics and relationship to plasma lipoproteins, Curr Opin Lipidol, 7, 69, 10.1097/00041433-199604000-00004 Watson, 1995, Protective effect of HDL associated paraoxonase; inhibition of biological activity of minimally oxidized low density lipoprotein, J Clin Invest, 96, 2882, 10.1172/JCI118359 Mackness, 1998, Human serum paraoxonase—review, Gen Pharmacol, 31, 329, 10.1016/S0306-3623(98)00028-7 Inoue, 2000, Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes, Metabolism, 49, 1400, 10.1053/meta.2000.17724 Mackness, 1991, Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus, Atherosclerosis, 86, 193, 10.1016/0021-9150(91)90215-O Laplaud, 1998, Paraoxonase as a risk marker for cardiovascular disease, Clin Chem Lab Med, 36, 431, 10.1515/CCLM.1998.073 Ruı́z, 1995, Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes, Lancet, 346, 869, 10.1016/S0140-6736(95)92709-3 Hegele, 1997, Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 82, 3373, 10.1210/jc.82.10.3373 Goth, 1991, A simple method for determination of serum catalase activity and revision of reference range, Clin Chim Acta, 196, 143, 10.1016/0009-8981(91)90067-M Sun, 1988, A simple method for clinical assay of superoxide dismutase, Clin Chem, 34, 497, 10.1093/clinchem/34.3.497 Eckerson, 1983, The human serum paraoxonase/arylsterase polymorphism, Am J Hum Genet, 35, 1126 Gowri, 1999, Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL, Arterioscler Thromb Vasc Biol, 19, 2226, 10.1161/01.ATV.19.9.2226 Redlock, 2000, Glycation impairs high-density lipoprotein function, Diabetologia, 43, 312, 10.1007/s001250050049 Ruı́z, 1997, Diabetes mellitus and the late complications, Diabetes Metab, 23, 57 Rema, 1995, Does oxidant stress play a role in diabetic retinopathy?, Indian J Ophthalmol, 43, 17 Watala, 1986, Peroxide metabolism enzymes in diabetic children, Cytobios, 47, 101 Freeman, 1982, Biology of disease, Lab Invest, 47, 412 Arai, 1987, Increase in the glycosylated form of erythrocyte Cu-Zn superoxide dismutase in diabetes and close association of the nonenzymatic glucosylation with the enzyme activity, Biochim Biophys Acta, 924, 292, 10.1016/0304-4165(87)90025-0 Jenner, 1994, Oxidative damage in neurodegenerative disease, Lancet, 344, 796, 10.1016/S0140-6736(94)92347-7